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P U B L I S H E D B Y E L S E V I E R I N C .LettersTranscatheter Mitral Valve
Replacement for the
Treatment of Mitral
Regurgitation
In-Hospital Outcomes of an
Apically Tethered DeviceMitral regurgitation (MR) is a leading cause of
valvular heart disease. Although conventional mitral
valve surgery is the gold standard, as many as 49% of
patients with severe MR may not undergo conven-
tional surgery (1). Following on from the successful
roll out of transcatheter aortic valve replacement
(TAVR), there have been some recent reports of
transcatheter mitral valve replacement (TMVR) (2,3).
However, an accompanying editorial highlighted
some of the difﬁcult challenges facing TMVR (4).
These include the broad spectrum of etiologies, le-
sions, and annular size and geometry of patients with
MR as well as the potential for device migration,
left ventricular outﬂow tract obstruction, and para-
valvular MR. All the devices implanted thus far
have been designed primarily to treat functional/
secondary MR and only exist in a single or limited
range of sizes (5). The aim of this brief research
communication is to report the ﬁrst-in-human (FIH)
implants with the Tendyne system.
This trileaﬂet porcine pericardial valve (Tendyne,
Roseville, Minnesota) is sewn onto an apically teth-
ered, self-expanding nitinol frame. The valve is
designed to ﬁt the anatomically complex mitral
annulus and can accommodate a wide range of sizes.
The outer stent is D shaped, which helps seat the
valve. The cuff is raised along the straight aspect of
the D shape. This element of the cuff is positioned in
relation to the aortic-mitral continuity. The tether
stabilizes the device, passing through the ventricular
myocardium where it is ﬁxed to an epicardial pad.
The device can be retrieved and/or repositioned
intraoperatively, even after full deployment.
Three-dimensional transesophageal echocardiog-
raphy (3DTEE) and multidetector computed to-
mography (MDCT) imaging were used for detailed
measurements of mitral annular dimensions andgeometry, as well as for deﬁning the optimal left
ventricular apical access location. On MDCT, the
annulus was evaluated using a modiﬁed method-
ology for assessing the D-shaped annulus, integrating
measures of septal-lateral and intercommissural di-
mensions. MDCT was also used to measure the aor-
tomitral angulation to assess the possible risk of
LVOT obstruction.
The valve size was chosen based on MDCT imaging
of the patient’s mitral annular dimensions conﬁrmed
by intraoperative 3DTEE. The device was implanted
with the patient under general anesthesia via a
transapical approach through a small left mini-
thoracotomy using a 34-French sheath that was
advanced over the wire into the left atrium. The
implant was advanced through the sheath until the
correct anatomic position of the D-shaped outer stent
could be visualized and conﬁrmed. The device was
then fully deployed. The apical pad was inserted into
position over the tether. The tension on the tether
was then adjusted to optimize the position of the
device. All of the above was effected predominantly
using 2- and 3-dimensional transesophageal echo-
cardiographic imaging.
The patient proﬁles are summarized in Table 1.
Patient 1 had twice undergone coronary artery bypass
graft operations and presented with severe functional
MR. Patient 2 also had previously undergone coro-
nary artery bypass grafting and presented with sig-
niﬁcant renal impairment and severe degenerative
MR. Patient 3 was a frail elderly man with severe
degenerative MR. All had >1 hospital admission with
overt heart failure in the 6 months before their im-
plantation. The ﬁrst 2 patients had been declined
conventional surgery at other U.K. cardiac surgical
centers. All went through our heart team evaluation
and were deemed not to be candidates for conven-
tional surgery and anatomically unsuitable for any
other CE-marked device. They were deemed suitable
for TMVR on a U.K. compassionate use protocol.
TMVR with this device was performed between
October 20 and November 11, 2014. There were no
procedural complications (Valve Academic Research
Consortium-2). All patients had no or trivial para-
valvular MR, no transvalvular MR, and no signiﬁcant
transmitral gradient (Table 1). All 3 patients were
discharged to their own home, independent in
TABLE 1 Patient Proﬁles
Patient #1 Patient #2 Patient #3
Age, yrs 68 75 87
Sex Female Male Male
Pre-TMVR NYHA functional class IV IV III
Glomerular ﬁltration rate, ml/min 47 18 44
Previous CABG Yes Yes No
Heart failure hospital admission
in previous 6 months
2 1 1
Etiology MR Secondary Primary Primary
Pre-TMVR MR grade (EROA, cm2) 0.34 0.79 1.39
Post-TMVR MR grade None Trivial None
Post-TMVR peak/mean mitral
gradient, mm Hg
8/3 11/5 7/2
Length of hospital stay, days 20 7 5
Discharge destination Home Home Home
CABG ¼ coronary artery bypass grafting; EROA ¼ effective regurgitant oriﬁce area;
MR ¼ mitral regurgitation; NHYA ¼ New York Heart Association; TMVR ¼ trans-
mitral valve replacement.
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2353activities of daily living, with the last patient being
discharged on the ﬁfth post-operative day. All have
reported a marked symptomatic improvement.
The complex pathoanatomy of the mitral valve will
present a difﬁcult challenge for TMVR compared with
TAVR. All the devices with early clinical experience
have their advantages and disadvantages, and much
work remains to be done before TMVR becomes a
viable therapeutic alternative to surgical valve repair/
replacement. However, the FIH experience with this
system is a promising beginning. Stabilization by
means of an apical tether is a novel way to attempt to
minimize the risk of device migration, left ventricular
outﬂow tract obstruction, and paravalvular leakage.
The unique design features of this device also offer
the potential for it to be useful across a wide range of
mitral valve pathologies.*Neil Moat
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in College AthletesSudden cardiac death (SCD) is the leading cause
of death in college athletes during sports (1). Pre-
participation examinations are required in college
athletes, although the best screening protocol to
identify cardiovascular diseases known to cause SCD
is debated. The purpose of this study was to
examine results from a single National Collegiate
Athletic Association (NCAA) Division I institution
with extensive experience conducting electrocar-
diograms (ECGs) in the cardiovascular screening of
athletes.
Routine 12-lead ECG screening of all intercollegiate
athletes undergoing pre-participation evaluations
at the University of Washington began in August
2010. The screening evaluation included a standard-
ized history questionnaire from the Pre-Participation
Physical Evaluation Monograph (4th edition), phys-
ical examination, and resting ECG. ECG interpretation
was guided by modern standards, and screening
abnormalities underwent additional evaluation in
consultation with cardiovascular specialists.
Findings were compared among student athletes
using the Fisher exact test, and statistical signiﬁcance
was deﬁned as p < 0.05. The primary outcome mea-
sure was the identiﬁcation of disorders associated
